IS3063B - CRF2 viðtakaverkar og notkun þeirra í meðferð - Google Patents

CRF2 viðtakaverkar og notkun þeirra í meðferð

Info

Publication number
IS3063B
IS3063B IS050392A IS050392A IS3063B IS 3063 B IS3063 B IS 3063B IS 050392 A IS050392 A IS 050392A IS 050392 A IS050392 A IS 050392A IS 3063 B IS3063 B IS 3063B
Authority
IS
Iceland
Prior art keywords
therapy
receptor antagonists
crf2 receptor
crf2
antagonists
Prior art date
Application number
IS050392A
Other languages
English (en)
Inventor
Stephane Illiano
Laurence Lucats
Laetitia Leden
Philippe Beauverger
Philip Janiak
Marie-Laure Ouzoux
Nils Halland
Ziyu Li
Ralf Elvert
Andreas Evers
Elisabetta Bianchi
Alessia Santoprete
Daniela Roversi
Martina Tripepi
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IS3063B publication Critical patent/IS3063B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS050392A 2020-08-19 2021-08-18 CRF2 viðtakaverkar og notkun þeirra í meðferð IS3063B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20315387 2020-08-19

Publications (1)

Publication Number Publication Date
IS3063B true IS3063B (is) 2025-06-15

Family

ID=72615799

Family Applications (1)

Application Number Title Priority Date Filing Date
IS050392A IS3063B (is) 2020-08-19 2021-08-18 CRF2 viðtakaverkar og notkun þeirra í meðferð

Country Status (16)

Country Link
US (1) US20250243255A1 (is)
EP (2) EP4199946B1 (is)
JP (1) JP2023541798A (is)
KR (1) KR20230051583A (is)
CN (1) CN116472053A (is)
AU (1) AU2021328673A1 (is)
CA (1) CA3192032A1 (is)
ES (1) ES2988026T3 (is)
HR (1) HRP20240906T1 (is)
HU (1) HUE066991T2 (is)
IL (1) IL300464A (is)
IS (1) IS3063B (is)
MX (1) MX2023002087A (is)
PL (1) PL4199946T3 (is)
WO (1) WO2022038179A1 (is)
ZA (1) ZA202301784B (is)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304214B2 (en) 2021-01-20 2025-01-01 Viking Therapeutics Inc Compositions and methods for treating metabolic and liver disorders
KR102873595B1 (ko) 2021-09-15 2025-10-22 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애의 치료를 위한 조성물 및 방법
EP4234574A1 (en) 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy
WO2025104264A1 (en) 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
WO2025222010A1 (en) * 2024-04-19 2025-10-23 Neurocrine Biosciences, Inc. Corticotropin releasing factor receptor 2 (crfr2) agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Also Published As

Publication number Publication date
EP4199946C0 (en) 2024-06-05
EP4199946B1 (en) 2024-06-05
EP4435001A2 (en) 2024-09-25
ES2988026T3 (es) 2024-11-19
HUE066991T2 (hu) 2024-09-28
IL300464A (en) 2023-04-01
CA3192032A1 (en) 2022-02-24
KR20230051583A (ko) 2023-04-18
AU2021328673A1 (en) 2023-03-30
EP4199946A1 (en) 2023-06-28
US20250243255A1 (en) 2025-07-31
MX2023002087A (es) 2023-03-23
PL4199946T3 (pl) 2024-08-19
ZA202301784B (en) 2024-01-31
WO2022038179A1 (en) 2022-02-24
HRP20240906T1 (hr) 2024-10-11
EP4435001A3 (en) 2024-10-09
CN116472053A (zh) 2023-07-21
JP2023541798A (ja) 2023-10-04

Similar Documents

Publication Publication Date Title
IS3063B (is) CRF2 viðtakaverkar og notkun þeirra í meðferð
SI3806955T1 (sl) Agonisti receptorja glp-1 in njihova uporaba
DK4058445T3 (da) Glp-1-receptoragonist og anvendelse deraf
IL282487A (en) Tyk2 inhibitors and uses thereof
IL286998A (en) Pyrimidinone history and their use as shp2 antagonists
DK3866376T3 (da) Fremgangsmåder med fysisk lag og mac-lag i en trådløs indretning
SI3658557T1 (sl) Zaviralci TYK2 in njihova uporaba
DK3707159T3 (da) Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf
EP3858856A4 (en) ANTI-B7-H3 MONOCLONAL ANTIBODY AND ITS USE IN CELLULAR THERAPY
IL286248B2 (en) Tyk2 inhibitors and uses thereof
IL284369A (en) Antibody against human il-4ra and use thereof
IS8190A (is) Ný P2X7 viðtakamótlyf og notkun þeirra
IS050770A (is) CRF2 viðtakaverkar og notkun þeirra í meðferð
DK3430037T3 (da) Transficerede t-celler og t-cellereceptorer til anvendelse i immunterapi mod cancere
BRPI0818766A2 (pt) N-fenil-pirrolidinilmetilpirrolidinamidas substituídas e uso terapêutico das mesmas
DK3423496T3 (da) Ikke-antagonistiske antistoffer rettet mod alfakæden i IL7-receptorens ekstracellulære domæne og anvendelse deraf i kræftbehandling
GB201802307D0 (en) CD36 antagonists for use in melanoma treatment
IL292693A (en) Mrgprx2 antagonists and uses thereof
IL312330A (en) Tyk2 degraders and uses thereof
GB202014736D0 (en) Novel compounds and their use in therapy
IL321519A (en) Multivalent and multispecific cytokine antagonists
IL280831A (en) Combination therapy with C-C antagonists such as cytokine receptor 4 (CCR4) and one or more immune checkpoint inhibitors
IL282926A (en) T cell receptors specific for mesothelin and their use in immunotherapy
EP4226673A4 (en) SCHEDULING AND RETRANSMISSION IN CENTRAL UNITS AND DISTRIBUTED UNITS
EP4326771A4 (en) CHIMERIC CYTOKINE RECEPTORS AND THEIR USES IN CELLULAR THERAPIES